Intercellular signaling by extracellular vesicles (EVs) is a route of cell-cell crosstalk that allows cells to deliver biological messages to specific recipient cells. EVs convey these messages through their distinct cargoes consisting of cytokines, proteins, nucleic acids, and lipids, which they transport from the donor cell to the recipient cell. In cardiovascular disease (CVD), endothelial-and immune cell-derived EVs are emerging as key players in different stages of disease development. EVs can contribute to atherosclerosis development and progression by promoting endothelial dysfunction, intravascular calcification, unstable plaque progression, and thrombus formation after rupture. In contrast, an increasing body of evidence highlights the beneficial effects of certain EVs on vascular function and endothelial regeneration. However, the effects of EVs in CVD are extremely complex and depend on the cellular origin, the functional state of the releasing cells, the biological content, and the diverse recipient cells. This paper summarizes recent progress in our understanding of EV signaling in cardiovascular health and disease and its emerging potential as a therapeutic agent. (J Am Coll Cardiol Basic Trans Science 2017;2:790-807)
BIOGENESIS OF EXTRACELLULAR VESICLES AND THEIR INTERACTIONS WITH TARGET CELLS
EVs are membrane vesicles secreted from cells that contain intracellular contents (11) . Cells can release a broad range of vesicles with diverse features. This review focuses on 2 major types: MVs and exosomes.
MVs are large (>150 nm) vesicles that are released by budding from the plasma membrane, whereas exosomes are smaller (30 to 100 nm) and originate from the endosome (12) . However, there is no strict cutoff value that distinguishes MVs from exosomes by vesicle size, which can differ in diverse studies (12) .
Exosomes represent a homogeneous population of vesicles that are formed by inward budding of the multivesicular body (MVB) membrane. Exosome biogenesis is mediated mainly by the endosomal sorting complex required for transport (ESCRT) protein (13) or lipid ceramide and neutral sphingomyelinase, the enzyme that converts sphingomyelin to ceramide (14) . Cargo sorting into exosomes involves ESCRT and associated proteins such as tumor susceptibility gene 101 protein (TSG101) and ALG-2-interacting protein X (ALIX) and small GTPases such as Rab7a and Rab27b (15) (16) (17) . Exosomes are liberated into the extracellular space following fusion of MVBs with the cell membrane, regulated by Rab27A, Rab11, and Rab31 (18, 19) . MVs represent a relatively heterogeneous population of vesicles formed by outward budding of the cell membrane. This process is regulated by membrane lipid microdomains and regulatory proteins such as ADP-ribosylation factor 6 (ARF6) (20) . EVs can be regarded as intercellular messengers for various biological processes. Several routes of interaction between EVs and recipient cells have been described. First, EVs can directly activate target cell surface receptors by bioactive ligands and proteins (21) (22) (23) . Second, EVs are able to transfer their biological content by membrane fusion with the recipient cell. The fusion process is regulated by the lipid composition of EV membrane, and several reports indicate that the presence of phosphatidylserine contributes to membrane fusion (24) . Third, incorporation of EVs into target cells is mediated by endocytosis, pinocytosis, or phagocytosis (25) . Through these interaction routes, EVs transfer their biological contents containing nucleic acids such as mRNA (26) , noncoding RNAs (miRNAs [27] , long noncoding RNAs [6] ), proteins (28) , cytokines (29) , or bioactive lipids (30) (Figure 1 ).
EXTRACELLULAR VESICLES AS EFFECTORS OF CARDIOVASCULAR DISEASES
In cardiovascular biology, EVs have various physiological functions, including activation of platelets and ECs, as well as regulation of inflammation and coagulation (31) (32) (33) (34) . Therefore, EVs are emerging as key players in different stages of CVD development (31, 32, 35) . The effects of EVs in CVD are extremely complex and depend on the cellular origin, the functional state of the releasing cells, the intravesicular content, and the recipient cells (36, 37) . The following sections summarize the current knowledge about EVs as effectors of CV disease progression or vascular repair.
DETRIMENTAL EFFECTS OF EXTRACELLULAR VESICLES
ON VASCULAR FUNCTION. Endothelial dysfunction occurs as a response to cardiovascular risk factors and represents the initial step in atherosclerosis development, the underlying pathology of CVD (38, 39) . 
In line with the latter findings, MVs isolated from patients with vascular (acute coronary syndrome Exosome formation starts with endocytosis, a process in which the cell membrane is pinched inward and captures bioactive molecules, resulting in the formation of the endosome. These molecules are sorted into smaller vesicles that bud from the perimeter membrane into the endosome lumen, forming vesicles; this leads to the multivesicular appearance of late endosomes and so they are also known as MVBs. From MSBs, exosome formation occurs by an ESCRT-and ceramide-dependent pathway. Cargo sorting into exosomes involves ESCRT and TSG101, ALIX, and Rab7a, and Rab27b. Exosomes are released into the extracellular space following the fusion of MVBs with the cell membrane, which is regulated by Rab27A, Rab11, and Rab31. Microvesicles are formed by the outward budding of the cell membrane, a process that is regulated by ARF6. Several routes of interaction between EVs and recipient cells have been described. First, EVs can directly activate target cell surface receptors. Second, EVs are able to transfer their biological content by membrane fusion with the recipient cell. Third, incorporation of EVs into target cells is mediated by endocytosis, pinocytosis, or phagocytosis. Using these interaction routes, EVs transfer their biological content containing nucleic acids such as mRNA, noncoding RNAs (microRNAs, long noncoding RNAs), proteins, cytokines, or bioactive lipids. mRNA ¼ messenger RNA; MVB ¼ multivesicular bodies. Jansen et al.
represents an important translational approach to exploring the relationship between EVs and certain diseases. However, comorbidities as well as patients' age and sex should be taken into consideration as possible confounders. Therefore, inclusion and exclusion criteria should be thoughtfully determined, and control groups must be carefully selected.
E n d o t h e l i a l a c t i v a t i o n , m o n o c y t e a d h e s i o n / i n fi l t r a t i o n , a n d i n fl a m m a t i o n . Inflammation plays a pivotal role in CVD (38, 47 
Endothelial and Immune Cell EVs in CV Health and Disease The functional effect of EVs in cardiovascular disease is extremely complex and depends on the cellular origin, the functional state of the releasing cells, the biological content, the distinct recipient cell, and the transfer capacity of intravesicular functional bioactive molecules.
Here, we illustrate the role of EVs as active promoters of endothelial dysfunction, vascular calcification, atherogenesis, plaque instability and Mesenchymal stem cells contribute to inflammatory Continued on the next page Jansen et al. Jansen et al.
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may show different results depending on the method used (152). Furthermore, there are no standard protocols (e.g., optimal EM-EV measurement protocols) (142) . Importantly, some methods, such as nanoparticle-tracking analysis or resistive pulse sensing, cannot distinguish membrane vesicles from nonmembranous particles of similar size, so the results should be compared by using EM, AFM, or other microscopy technique (153) . However, few data are available studying concrete mechanisms regulating MV release and clearance.
Moreover, physiological models are not well established (e.g., considering time-dependent release kinetics of EVs from parent cells). Finally, the absence of adequate in vivo models to explore the generation and uptake of cell-specific EVs limits the experimental opportunities to study EV functions in vivo.
U n c l e a r p r o c e s s i n g o f E V s a n d t h e i r c o n t e n t a f t e r c e l l u l a r u p t a k e . 
